Myeloproliferative Neoplasms (MPN)

Latest News
April 25th 2024

Lack of Mutations Associated With Favorable Prognosis in MPN-U

April 12th 2024

Utilization of Momelotinib for Myelofibrosis With Anemia Can Result in Small Savings

April 6th 2024

Follow-Up Needs for Blood Cancer Survivors May Determine Best Type of Provider

March 27th 2024

Younger Patients With PV May Benefit From Earlier Treatment With Cytoreductive Therapies

March 26th 2024

Pegylated Interferons Have Promise but Also Unmet Potential in MPNs

AJMC Provides Myelofibrosis Guideline Updates

Watch the series now!

AJMC Provides Myelofibrosis Guideline Updates
Video Interviews
View All
April 20th 2024

New Data Challenge Traditional Treatment Paradigm in MPNs, Says Dr Raajit Rampal

April 7th 2024

Dr Raajit Rampal Discusses Disease Modification and Emerging Therapies in Polycythemia Vera

April 1st 2024

Emerging Data Continue to Evolve Treatment Utilization in MPNs

March 22nd 2024

Dr Raajit Rampal Highlights Emerging Therapies in MPNs

March 1st 2024

Dr Jennifer Vaughn: Patients With MPN, MDS Should Discuss Long-Term Priorities Upfront

More News

Primary myelofibrosis cells | Image credit: LASZLO - stock.adobe.com
March 16th 2024

Disease-, Age-, Genomic-Specific Factors Increase Risk of ET, PV, PrePMF Developing Into Overt MF

Laura Joszt, MA
New research highlights the factors that increase the likelihood that essential thrombocytopenia (ET), polycythemia vera (PV), and prefibrotic primary myelofibrosis (PrePMF) will evolve into overt myelofibrosis (MF).
Polycythemia vera red blood cells | Image credit: Dr_Microbe - stock.adobe.com
March 13th 2024

Patients With MPNs Have Increased Risk of Thrombosis, Hemorrhage, Leukemic Transformation

Laura Joszt, MA
Compared with matched controls, patients with myeloproliferative neoplasms (MPNs) had a higher risk of developing thrombosis, hemorrhage, and leukemic transformation, according to a longitudinal cohort study.
Distressed young woman of color | Image credit: Diego Cervo - stock.adobe.com
March 8th 2024

AYA With MPN Face Psychological Needs That Are Poorly Understood

Laura Joszt, MA
A review of research confirms that adolescents and young adults (AYA) with myeloproliferative neoplasms (MPN) face psychological burdens but the exact burden is poorly understood.
National Comprehensive Cancer Network (NCCN) logo | Image credit: NCCN
March 6th 2024

NCCN Lists Ropeginterferon Alfa-2B as Preferred First-Line Cytoreductive Therapy for Polycythemia Vera

Ashling Wahner
The National Comprehensive Cancer Network (NCCN) recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.
Doctor Measuring arterial blood pressure man patient Health care in hospital | joyfotoliakid - stock.adobe.com
December 7th 2023

Reducing Cardiovascular Risk in Patients With Polycythemia Vera

Pearl Steinzor
Polycythemia vera (PV) therapy should aim to identify cardiovascular risk factors, according to one review.
Diagnosis of Myelofibrosis. Laboratory blood bottle (tube), glass slide with blood smear, hematology test, stethoscope lying on notebook with printed text hematological diagnosis of Myelofibrosis | shidlovski - stock.adobe.com
November 17th 2023

Enhancing Outcomes and Quality of Life for Patients With Myelofibrosis

Pearl Steinzor
A phase 3 trial in symptomatic and anemic patients with myelofibrosis (MF) met its primary end point, seeing a significant symptom reduction at 24 weeks with momelotinib vs danazol.
Rare diseases inscription words. Medical concept of unusual disorders | valiantsin - stock.adobe.com
October 24th 2023

The Effects of Aging on Profiling Epigenetic Changes in Myeloproliferative Neoplasms

Pearl Steinzor
Researchers identified distinct patterns of epigenetic dysregulation in myeloproliferative neoplasms.
Myeloproliferative Disorders. Myeloproliferative Disorders disease blood test inmedical laboratory: © luchschenF - stock.adobe.com
May 15th 2023

Review Highlights Features, Treatment of Budd-Chiari Syndrome in MPNs

Gianna Melillo
Budd-Chiari syndrome and myeloproliferative neoplasms (MPNs) are rare, which means available data are limited.
Yoga
November 12th 2020

Integrative Medicine Shows Benefits for Patients With MPNs

Jaime Rosenberg
A recent survey of patients with myeloproliferative neoplasms found integrative medicine interventions improved symptom burden, fatigue, depression, and improved quality of life.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo